NCT05367973View on ClinicalTrials.gov

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

January 9, 2023

Study Completion Date

March 23, 2023

Conditions
Vulvovaginal AtrophyVasomotor Symptoms
Interventions
DEVICE

IVR Dose 1

Estradiol 80 ug/day + progesterone 4 mg/day

DEVICE

IVR Dose 2

Estradiol 160 ug/day + progesterone 8 mg/day

Trial Locations (2)

5000

PARC Clinical Research, Adelaide

6009

Keogh Institute for Medical Research, Nedlands

Sponsors
All Listed Sponsors
lead

Daré Bioscience, Inc.

INDUSTRY